Moffitt Cancer Center researchers have uncovered groundbreaking insights into the LAG3 protein, a crucial player in cancer immunotherapy. Their findings reveal how LAG3 interacts with immune cells, potentially paving the way for more effective cancer treatments. By blocking LAG3, this discovery could help immune checkpoint inhibitors target cancer cells more precisely, boosting the immune system's ability to fight tumours. This breakthrough offers new hope for transforming cancer immunotherapy approaches and advancing patient outcomes. Learn more: https://lnkd.in/ejshymr6 #immunotherapy #cancer #research
Carcinotech Ltd
Biotechnology Research
Edinburgh, Midlothian 3,679 followers
Reinventing Cancer Research
About us
Carcinotech has pioneered the development of assay-ready, 3D-bioprinted tumours derived from patient biopsies for oncology drug discovery and development. Carcinotech’s tumours are uniquely engineered to preserve cancer heterogeneity by encompassing multiple cell types present in the donor tumour microenvironment, including cancer, stromal, specialized microenvironment, immune, and cancer stem cells. This physiologically and genetically relevant model offers superior predictive power compared to traditional organoid and animal models, improving drug discovery, optimization, and pre-clinical testing efficiencies, thereby shortening the path to bringing a new oncology therapy to market.
- Website
-
http://www.carcinotech.co.uk
External link for Carcinotech Ltd
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Edinburgh, Midlothian
- Type
- Privately Held
- Founded
- 2018
- Specialties
- Precision oncology, Cancer research, 3D bioprinting , Drug discovery , Cancer microenvironment, Personalised medicine testing, drug testing, oncology, assay services, biobank, oncology pre-clinical services, solid tumours, solid tumors, tumour microenvironment, tumor microenvironment, immuno-oncology, early phase drug development, and immune cells
Locations
-
Primary
Roslin Innovation Centre
Easter Bush Campus
Edinburgh, Midlothian EH25 9RG, GB
Employees at Carcinotech Ltd
Updates
-
We're hiring! We are looking for a new biomedical scientist to expand our fantastic scientific team. Join us on our mission to accelerate the development of cancer therapies and enjoy several perks including: 💙 A close-knit team 🏥 Private healthcare 🌳 Beautiful surroundings 🤸♂️ Discounted campus gym 👼 On-site nursery 🚌 Great public transport links 🤘 Regular social events 💡 Working within a collaborative startup community Visit the link below for more information about the role and how to apply. #jobopportunity #STEM #careersinSTEM
-
Thank you to ELRIG UK for hosting such an insightful event yesterday! The Drug Discovery Scotland Forum highlighted the dynamic and diverse landscape of Scotland’s drug discovery sector, reaffirming its role as a leader in healthcare innovation. Looking forward to seeing the breakthroughs that lie ahead! #ELRIGUK #DrugDiscovery #FutureofMedicine
-
Carcinotech Ltd reposted this
A Breakthrough in Lung Cancer Research! ⬇ Are you exploring new avenues in lung cancer treatment? As a researcher, you know the limitations of traditional 2D cultures and animal models that fail to mimic human tumours accurately. Carcinotech’s Carcino3D™ Lung Model overcomes these challenges by providing a physiologically relevant, 3D-bioprinted model that accurately replicates the lung tumour microenvironment, enabling more reliable pre-clinical testing and drug discovery! Here are a few key advantages of using the Carcino3D™ Lung Model: ✅ RELEVANT = Our 3D-bioprinted tumours incorporate patient-derived cells (including immune cells) maintaining the genetic and physiological properties of the original tumour. ❇ REPRODUCIBLE = Automated bioprinting ensures consistency across each tumour, providing reliable data to accelerate drug development. ✳ RESPONSIVE = Our lung model closely matches the in vivo responses to standard-of-care drugs, showing it can effectively predict how these treatments work. Are you interested in advancing your research with our innovative model? Download our latest application note to discover how our Carcino3D™ platform can transform your approach to lung cancer research. Download here: https://lnkd.in/ekKxmqMp #3DCancerModels #Lung #Cancer #Drug #Discovery #CancerResearch
Application Note: Carcino3D™ Lung Model as a Relevant Tool for Drug Testing - Carcinotech Ltd
https://www.carcinotech.co.uk
-
A Breakthrough in Lung Cancer Research! ⬇ Are you exploring new avenues in lung cancer treatment? As a researcher, you know the limitations of traditional 2D cultures and animal models that fail to mimic human tumours accurately. Carcinotech’s Carcino3D™ Lung Model overcomes these challenges by providing a physiologically relevant, 3D-bioprinted model that accurately replicates the lung tumour microenvironment, enabling more reliable pre-clinical testing and drug discovery! Here are a few key advantages of using the Carcino3D™ Lung Model: ✅ RELEVANT = Our 3D-bioprinted tumours incorporate patient-derived cells (including immune cells) maintaining the genetic and physiological properties of the original tumour. ❇ REPRODUCIBLE = Automated bioprinting ensures consistency across each tumour, providing reliable data to accelerate drug development. ✳ RESPONSIVE = Our lung model closely matches the in vivo responses to standard-of-care drugs, showing it can effectively predict how these treatments work. Are you interested in advancing your research with our innovative model? Download our latest application note to discover how our Carcino3D™ platform can transform your approach to lung cancer research. Download here: https://lnkd.in/ekKxmqMp #3DCancerModels #Lung #Cancer #Drug #Discovery #CancerResearch
Application Note: Carcino3D™ Lung Model as a Relevant Tool for Drug Testing - Carcinotech Ltd
https://www.carcinotech.co.uk
-
🌟 Exciting News!🌟 Our CEO Ishani Malhotra, will speak on the ‘Financing 101’ panel at tomorrow's Female Founders Growth Summit. This event, hosted by Pathways Forward and Female Founders Rise, connects scale-up stage founders with key stakeholders and investors in Scotland's female entrepreneurship ecosystem. During the panel, Ishani will share her journey as a female founder, highlighting the importance of directing investment into female enterprises and addressing the inequalities in VC funding. Find the event live stream here: https://lnkd.in/ePVFkHN2 - limited spaces are available so register ASAP to ensure you don't miss out. Wishing everyone an insightful and impactful summit! #WomenInBusiness #FemaleEntrepreneurship #MovingForwardFaster
Welcome! You are invited to join a webinar: Female Founders Growth Summit. After registering, you will receive a confirmation email about joining the webinar.
rbs.zoom.us
-
🚀 We're thrilled to release our latest application note: Carcino3D™ Lung Model as a Relevant Tool for Drug Testing. Dive into the data demonstrating how 3D-printed lung tumours can serve as a valuable tool in developing lung cancer therapeutics. Download now: https://lnkd.in/ekKxmqMp #LungCancer #3DCancerModels #CancerResearch
-
🚀 Exciting Progress in Prostate Cancer Treatment! 🚀 A recent study by City of Hope reveals promising results for CAR-T cell therapy in treating prostate cancer. The study demonstrated that CAR-T therapy, which re-engineers a patient's immune cells to target and destroy cancer, can achieve tumour regression and improved patient outcomes. This groundbreaking approach, previously successful in blood cancers, now offers hope for men battling prostate cancer by providing a new, potentially life-saving treatment option. Read more about this innovative therapy and its potential to revolutionise prostate cancer care: https://lnkd.in/ezbgtp2u #ProstateCancer #CARTtherapy #CancerResearch #InnovationInHealthcare
Study: CAR T for Prostate Cancer Shows Efficacy
cityofhope.org
-
Cell therapies, particularly CAR-T cells, have revolutionised blood cancer treatment by equipping T-cells with chimeric antigen receptors (CARs) to better recognise and target cancer-specific antigens. However, the challenge of treating solid tumours—due to their heterogeneity and the lack of specific surface antigens—has made developing CAR-T therapies for these cancers largely unsuccessful. That is, until now. This month, the FDA approved Tecelra, the first T-cell receptor (TCR) therapy for solid tumours, specifically for treating adults with metastatic synovial sarcoma. Unlike CAR-Ts, TCR therapies are minimally engineered and can target both cell surface and intracellular antigens. This breakthrough represents a pivotal moment in the treatment of this rare cancer, where five-year survival rates can be as low as 20% and no new therapies have reached the market in over a decade. Read more: https://lnkd.in/eZJu_B9Q
Adaptimmune leads soft tissue sarcoma therapy with TCR approval
pharmaceutical-technology.com
-
Joining us last week, we would like to welcome James Adams to the team! 🤝 With a background in pharmacology and an MSc in Tissue Engineering, James has a strong understanding of advanced in vitro modelling and bio-engineering techniques to develop better pre-clinical models. After graduating from his Masters, he worked as a research scientist at Defence Science Technology Laboratories where he worked on a series of lab-based projects and gained experience with various molecular techniques. As our newest imaging scientist at Carcinotech, James will be applying his experience in microscopy to expand our imaging capability and to support the team with ongoing client work. Welcome aboard James, it's great to have you!